Dampening expectations


Dampening expectations

Regeneron Pharmaceuticals Inc. stock responded negatively to the company's disclosure last week that there was no significant difference between drug and placebo in its Phase II trial of ciliary neurotrophic factor to treat amyotrophic lateral sclerosis. But the small size of the trial makes it impossible to draw many conclusions about CNTF's efficacy.

REGN shares had

Read the full 591 word article

How to gain access

Continue reading with a
two-week free trial.